Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Artificial Intelligence In Vitro Diagnostics Coronavirus COVID-19

Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests

Executive Summary

Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.

You may also be interested in...



Spanish Team’s AI Model For Pandemic Response Named XPRIZE Winner

VALENCIA IA4COVID19’s AI model won the XPRIZE Pandemic Response Challenge grand prize. Researchers are pinning their hopes on AI to help predict the next pandemic, but also for early diagnosis of COVID-19.

Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval

Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Table

View full table

Related Content

In Vivo
Scrip
Medtech Insight

Topics

Related Companies

Tags:
Artificial Intelligence In Vitro Diagnostics Coronavirus COVID-19
UsernamePublicRestriction

Register

MT143461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By